CAS: 442201-24-3; Ethyl (((2R,3S,4S,5R,6S)-3,4,5-Trihydroxy-6-((4-(4-Isopropoxybenzyl)-1-Isopropyl-5-Methyl-1H-Pyrazol-3-yl)Oxy)Tetrahydro-2H-Pyran-2-yl)Methyl) Carbonate

上下游产品

[14C]-Remogliflozin 329045-45-6
1-Acetyl-4-[(4-Isopropoxyphenyl)Methyl]-5-Methyl-3-(2,3,4,6-Tetra-O-Pivaloyl-β-D-Glucopyranosyloxy)-1H-Pyrazole
4-[(4-Isopropoxyphenyl)Methyl]-5-Methyl-3-(2,3,4,6-Tetra-O-Pivaloyl-β-D-Glucopyranosyloxy)-1H-Pyrazole 910054-55-6

2,3,4,6-O-四特戊酰基-Alpha-D-溴代吡喃葡萄糖置于吡啶,2,6-二甲基吡啶,1,3-二甲基-2-咪唑啉酮,甲醇,Sodium Methylate,Sodium Hydride,Potassium Carbonate,Potassium Hydrogencarbonate体系中,用 甲醇,正庚烷,甲基叔丁基醚,水,乙腈 作为反应溶剂,化学反应 22.0H,反应生成 瑞格列净
参考文献:通过n1-乙酰化作用将4-(取代的苄基)-1,2-二氢-3H-吡唑-3-一衍生物与2,3,4,6-四-O-酰基-α-D-吡喃葡萄糖基溴化物进行o-糖基化吡唑环.
标题:通过n1-乙酰化作用将4-(取代的苄基)-1,2-二氢-3H-吡唑-3-一衍生物与2,3,4,6-四-O-酰基-α-D-吡喃葡萄糖基溴化物进行o-糖基化吡唑环.
摘要:描述了4-(取代的苄基)-3-(2,3,4,6-四-O-酰基-β-D-吡喃葡萄糖基氧基)-1H-吡唑衍生物2的实用制备.通过在吡唑的n1位引入吸电子取代基,例如乙酰基,可以促进4-(取代的苄基)-1,2-二氢-3H-吡唑-3-酮衍生物3的o-糖基化.戒指.1-乙酰基-4-(取代的苄基)-1,2-二氢-3H-吡唑-3-酮10与2,3,4,6-四-O-酰基-α-D-吡喃葡萄糖基溴化物5反应在乙腈中存在碳酸钾以提供1-乙酰基-4-(取代的苄基)-3-(2,3,4,6-四-O-酰基-β-D-吡喃葡萄糖基氧基)-1H-吡唑衍生物11高产.当将2,3,4,6-四-O-新戊酰基-α-D-吡喃葡萄糖基溴化物(5B)用作糖基供体时,在甲醇中存在碳酸氢钾的情况下,将所得的o-糖基化产物11 N1-脱乙酰基,而糖基部分的去保护作用不佳,从而以优异的产率提供了2.使用该策略合成了莫格列净依替膦酸酯的合成中间体2B(1B).
DOI:10.1248/cpb.C15-00982

专利信息

专利号:US-12358903-B2
优先权日:2016-06-13
标题 :FXR (NR1H4) modulating compounds
发明人：BLOMGREN PETER A; CURRIE KEVIN S; FARAND JULIE; GEGE CHRISTIAN; KROPF JEFFREY E; XU JIANJUN
权利人:GILEAD SCIENCES INC
摘要:The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

专利号:US-11739065-B2
优先权日:2016-06-13
标题 :FXR (NR1H4) modulating compounds
发明人：BLOMGREN PETER A; CURRIE KEVIN S; GEGE CHRISTIAN; KROPF JEFFREY E; XU JIANJUN
权利人:GILEAD SCIENCES INC
摘要:The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

专利号:EP-2668953-A1
优先权日:2008-05-22
标 题:Pharmaceutical compositions comprising an SGLT2 inhibitor with a supply of carbohydrate and/or an inhibitor of uric acid synthesis